The ALIAS Pilot Trial. A dose-escalation and safety study of albumin therapy for acute ischemic stroke - I: Physiological responses and safety results

Stroke

Volumn 37, Issue 8, 2006, Pages 2100-2106

  Ginsberg, Myron D ^a   Hill, Michael D ^b   Palesch, Yuko Y ^c   Ryckborst, Karla J ^b   Tamariz, Diego ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ischemia; Neuroprotection; Outcome; Stroke; Thrombolysis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; HUMAN ALBUMIN; TISSUE PLASMINOGEN ACTIVATOR; ALBUMINOID; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; SERUM ALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; BARTHEL INDEX; BRAIN FUNCTION; BRAIN HEMORRHAGE; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FEMALE; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEMODILUTION; HUMAN; LUNG CONGESTION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MONITORING; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; RANKIN SCALE; ST SEGMENT DEPRESSION; VITAL SIGN; BLOOD; BRAIN ISCHEMIA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PILOT STUDY; TREATMENT OUTCOME;

AGED; ALBUMINS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NEUROPROTECTIVE AGENTS; PILOT PROJECTS; PULMONARY EDEMA; SERUM ALBUMIN; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33747195315     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000231388.72646.05     Document Type: Article

References (20)

1. Ginsberg MD. Neuroprotection in brain ischemia - an update - parts I and II. Neuroscientist. 1995;1:95-103, 164-175.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391-397.
3. Cheng YD, Al Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx. 2004;1:36-45.
4. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 1996;27:1616-1622.
5. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg. 1997;87:595-601.
6. Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, Busto R, Ginsberg MD. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29:2587-2599.
7. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke : marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32:553-560.
8. Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol. 2001;428:193-201.
9. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res. 1998;804:105-113.
10. Belayev L, Pinard E, Nallet H, Seylaz J, Liu Y, Riyamongkol P, Zhao W, Busto R, Ginsberg MD. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 2002;33:1077-1084.
11. Rodriguez de Turco EB, Belayev L, Liu Y, Busto R, Parkins N, Bazan NG, Ginsberg MD. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem. 2002;83:515-524.
12. Ginsberg MD, Belayev L, Bazan NG, Marcheselli VL, Hill MD, Palesch YY, Khoutorova L, Rodriguez de Turco EB, Ryckborst K, Tamariz D, Busto R. Albumin-based neurotherapeutics for acute ischemic stroke: from bench to bedside. In: Krieglstein J, Klumpp S, eds. Pharmacology of Cerebral Ischemia 2004. Stuttgart: Medpharm Scientific Publishers; 2004.
13. Belayev L, Khoutorova L, Belayev A, Zhang Y, Zhao W, Busto R, Ginsberg MD. Delayed post-ischemic albumin treatment neither improves nor worsens the outcome of transient focal cerebral ischemia in rats. Brain Res. 2004;998:243-246.
14. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000;355:1670-1674.
15. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989;45:925-937.
16. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
17. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol. 2004;44:740-749.
18. Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol. 1991;12:1123-1126.
19. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
20. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32:1598-1606.